Palatin Technologies
Patronus Resources Ltd is a gold exploration company. The company is engaged in the exploration and development of gold properties. It holds a 100% interest in the Cardinia Gold Project.
Clinical Trials
13
3 active
Approvals
1
Total approvals
Agencies
1
Regulatory bodies
Founded
1986
Active, not recruiting
3
23.1%
Completed
8
61.5%
Terminated
1
7.7%
Withdrawn
1
7.7%
- Palatin Technologies reported significant progress on its melanocortin-based obesity programs, with oral small molecule PL7737 advancing toward IND submission and Phase 1 clinical trials in the first half of 2026. - The company secured $18.2 million in public offering proceeds and achieved key milestones in its Boehringer Ingelheim collaboration, receiving €2.0 million upfront and €5.5 million research milestone payments. - Palatin's MC4R agonist programs target both broad obesity indications and rare forms like hypothalamic obesity, addressing significant unmet medical needs with no currently approved pharmacologic treatments. - The company regained NYSE American compliance and reported net income of $4.7 million for Q1 fiscal 2026, marking a turnaround from the previous year's $7.8 million loss.
- Palatin Technologies presented data at ObesityWeek 2025 showing their oral MC4R agonist PL7737 demonstrated dose-dependent weight loss and favorable safety profile in preclinical models. - Clinical data from the BMT-801 study revealed that combining an MC4R agonist with tirzepatide led to greater weight loss than tirzepatide alone without additional safety concerns. - The FDA has granted Orphan Drug Designation to PL7737 for leptin receptor deficiency-related obesity, with IND filing and Phase 1 trials planned for the first half of 2026.
- Palatin Technologies closed a reduced public offering raising approximately $1.1 million in gross proceeds through the sale of 7.3 million shares at $0.15 per share with accompanying warrants. - The company transitioned to trading on the OTC Pink market and issued three series of warrants with varying exercise prices and expiration terms to institutional and accredited investors. - Proceeds will be used primarily for working capital and general corporate purposes as the melanocortin receptor-focused biopharmaceutical company continues developing first-in-class medicines. - The offering structure includes potential additional funding of up to $1.1 million if milestone-related Series G warrants are exercised within specified timeframes.
- Palatin Technologies has presented preclinical data for PL9588, a novel melanocortin receptor agonist that demonstrates both IOP-lowering and neuroprotective effects for glaucoma treatment. - Unlike conventional glaucoma therapies that only reduce intraocular pressure, PL9588 provides additional retinal neuroprotection, reducing retinal cell stress by approximately 25% and decreasing retinal ganglion cell death in preclinical models. - The global glaucoma market, valued at $5.71 billion in 2021 and projected to reach $9.77 billion by 2030, highlights significant commercial potential for innovative dual-action therapies like PL9588.
- Updated Phase 3 analyses reveal PL9643 achieved complete symptom resolution across multiple endpoints in dry eye disease patients, a breakthrough not seen with any currently FDA-approved therapy. - The melanocortin receptor agonist demonstrated statistically significant symptom clearing by week 2, with continued improvement through week 12, while placebo effects plateaued early. - With 38 million Americans affected by dry eye disease but only a fraction receiving prescription treatment, PL9643's safety profile and rapid efficacy position it as a potential first-in-class therapy in a market projected to reach $7.46 billion by 2029.
- Palatin Technologies' Phase 2b BREAKOUT study demonstrated that 71% of patients with Type 2 diabetic nephropathy achieved significant reductions in proteinuria and showed improved or stabilized kidney function after six months of treatment. - The melanocortin agonist bremelanotide showed potential to preserve kidney structure, with 36% of patients experiencing reduced urinary synaptopodin loss and 37.5% showing increased urinary VEGF levels, suggesting improved vascular support. - This represents Palatin's third major clinical milestone across different therapeutic areas, following positive results in obesity and ulcerative colitis studies, validating their melanocortin platform approach.
- PL8177, a selective melanocortin-1 receptor agonist, achieved 33% clinical remission and 78% clinical response in ulcerative colitis patients compared to 0% and 33% for placebo, respectively, after eight weeks of treatment. - The novel oral therapy demonstrated an excellent safety profile with no reported adverse events, potentially offering an alternative to immunosuppressive and steroid therapies for ulcerative colitis patients. - Palatin Technologies has reported that licensing discussions are advancing with multiple pharmaceutical companies following these positive Phase 2 results, which could accelerate the development pathway for this first-in-class treatment.
- A fixed-dose combination of cagrilintide and semaglutide led to greater weight loss at 68 weeks compared to either drug alone or placebo in the REDEFINE 1 trial. - The FDA expanded the indication for setmelanotide (Imcivree) to include children as young as 2 years with specific types of genetic obesity. - Palatin Technologies reported that 71% of patients with type 2 diabetic nephropathy achieved a significant reduction in urine protein in a phase IIb study with bremelanotide.
- Palatin Technologies' Bremelanotide demonstrated positive results in a Phase IIb trial for Type 2 Diabetic Nephropathy, a leading cause of end-stage renal disease. - The BREAKOUT study showed that 71% of patients achieved a significant reduction in urine protein to creatinine ratio (UP/Cr) after six months. - The trial also reported that 71% of patients experienced either improved or stabilized estimated glomerular filtration rate (eGFR) with Bremelanotide treatment. - Bremelanotide was well-tolerated, with the most common adverse event being skin hyperpigmentation, suggesting potential for melanocortin agonists in treating DN.
- Palatin Technologies has completed enrollment in its Phase 2 study of oral PL8177 for ulcerative colitis, with topline data expected in Q1 2025. - Preclinical data suggests PL8177 may resolve damaging inflammation in the colon, offering a potential alternative to immunosuppressants. - Palatin also completed a Phase 2 trial of bremelanotide with tirzepatide for obesity, with topline data anticipated later this quarter. - The combination therapy targets the MC4R pathway, potentially leading to additive weight loss effects beyond GLP-1/GIP drugs.
